BioSpace News Archive

Bio-Techne Corporation Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells for use in both research and translational workflows.

PureTech Health plc today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021 at 4:35 PM EDT.

inTRAvent’s Bedside Neuro-Navigation Device Receives FDA 510(k) Clearance

Stealth BioTherapeutics Corp announced today that multiple abstracts have been accepted for presentation at several leading ophthalmic conferences this fall.

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

Immunophotonics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of metastatic cancers, has announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11111316.

Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, announced today that it has licensed exclusive worldwide rights to develop and commercialize a novel, oral, small molecule, SRC/YES1 inhibitor from the University of Edinburgh in Scotland.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced the formation of and initial appointments to its Scientific Advisory Board (SAB).

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021.

Cloud computing is one of the most commonly used applications in healthcare. Healthcare organizations are highly concerned about the privacy and security of patient information, and the pressure of managing the growing healthcare data has driven the implementation of cost effective solutions such as cloud computing.